Patricia T Greipp

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5046547/publications.pdf

Version: 2024-02-01

168 papers	3,042 citations	159585 30 h-index	197818 49 g-index
169 all docs	169 docs citations	169 times ranked	4637 citing authors

#	Article	IF	Citations
1	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood, 2017, 129, 3419-3427.	1.4	335
2	DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Modern Pathology, 2015, 28, 822-829.	5.5	142
3	Idiopathic Systemic Capillary Leak Syndrome (Clarkson's Disease): The Mayo Clinic Experience. Mayo Clinic Proceedings, 2010, 85, 905-912.	3.0	137
4	Diagnosis and Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
5	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood, 2016, 128, 1234-1245.	1.4	105
6	Antiâ€CD20 monoclonal antibody therapy in multiple myeloma. British Journal of Haematology, 2008, 141, 135-148.	2.5	98
7	Gastroblastoma harbors a recurrent somatic MALAT1â€“GLI1 fusion gene. Modern Pathology, 2017, 30, 1443-1452.	5.5	93
8	Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood, 2018, 131, 2262-2266.	1.4	77
9	Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Letters, 2016, 380, 163-173.	7.2	72
10	Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. Journal of Hematology and Oncology, 2019, 12, 73.	17.0	71
11	Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases. Modern Pathology, 2014, 27, 113-127.	5.5	65
12	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal, 2020, 10, 82.	6.2	59
13	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances, 2020, 4, 3509-3519.	5.2	58
14	Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1â€PRKACA fusion. Hepatology, 2018, 68, 1441-1447.	7.3	48
15	Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Modern Pathology, 2018, 31, 141-149.	5.5	47
16	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May HarborMYD88L265P Mutations. American Journal of Clinical Pathology, 2016, 145, 843-851.	0.7	43
17	False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms. Haematologica, 2019, 104, e248-e251.	3.5	43
18	Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study. Human Pathology, 2019, 87, 65-74.	2.0	41

#	Article	IF	Citations
19	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	5.2	41
20	Ibrutinib monotherapy outside of clinical trial setting in WaldenstrÃ¶m macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	2.5	41
21	Histopathologic and Cytogenetic Features of Pulmonary Adenoid Cystic Carcinoma. Journal of Thoracic Oncology, 2015, 10, 1570-1575.	1.1	40
22	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	7.2	40
23	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	6.2	38
24	Polypoid fibroadipose tumors of the esophagus: â€˜giant fibrovascular polypâ€™ or liposarcoma? A clinicopathological and molecular cytogenetic study of 13 cases. Modern Pathology, 2018, 31, 337-342.	5.5	37
25	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 73.	6.2	37
26	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. Blood Cancer Journal, 2018, 8, 97.	6.2	36
27	Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. British Journal of Haematology, 2013, 163, 326-333.	2.5	35
28	Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. European Journal of Haematology, 2019, 102, 87-96.	2.2	35
29	Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma. American Journal of Surgical Pathology, 2018, 42, 256-263.	3.7	34
30	Analysis of MDM2 Amplification in 43 Endometrial Stromal Tumors. International Journal of Gynecological Pathology, 2015, 34, 576-583.	1.4	33
31	Impact of MYD88^{L265P} mutation status on histological transformation of WaldenstrÃ¶m Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	4.1	33
32	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	7.0	32
33	Prevalence, breakpoint distribution, and clinical correlates of t(5;12). Cancer Genetics and Cytogenetics, 2004, 153, 170-172.	1.0	31
34	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	6.2	30
35	Loss of p16 INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas. Journal of Thoracic Oncology, 2017, 12, 860-871.	1.1	28
36	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	7.2	28

#	Article	IF	Citations
37	Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. Blood Cancer Journal, 2019, 9, 103.	6.2	27
38	De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity. Modern Pathology, 2018, 31, 705-717.	5.5	25
39	Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. Cancer Genetics, 2018, 228-229, 197-217.	0.4	25
40	Clinical utility of myb rearrangement detection and p63/p40 immunophenotyping in the diagnosis of adenoid cystic carcinoma of minor salivary glands: a pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 121, 282-289.	0.4	21
41	KMT2A (MLL) rearrangements observed in pediatric/young adult Tâ€lymphoblastic leukemia/lymphoma: A 10â€year review from a single cytogenetic laboratory. Genes Chromosomes and Cancer, 2018, 57, 541-546.	2.8	21
42	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances, 2020, 4, 2236-2244.	5.2	20
43	BCRâ€“JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. Cancer Genetics, 2016, 209, 223-228.	0.4	19
44	Acute leukemias harboring KMT2A/MLLT10 fusion: a 10â€year experience from a single genomics laboratory. Genes Chromosomes and Cancer, 2019, 58, 567-577.	2.8	19
45	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. Human Pathology, 2021, 112, 20-34.	2.0	19
46	Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders with Biallelic Rearrangements of DUSP22. Journal of Investigative Dermatology, 2013, 133, 1680-1682.	0.7	17
47	Atypical lipomatous tumour/wellâ€differentiated liposarcoma and deâ€differentiated liposarcoma in patients agedÂâ‰Â40Âyears: a study of 116 patients. Histopathology, 2019, 75, 833-842.	2.9	16
48	Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies. Blood Advances, 2019, 3, 1298-1302.	5.2	16
49	Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining. Cancer Research, 2021, 81, 3333-3346.	0.9	16
50	FISH Scoring for CLL: Comparison of Methods That Assess Round Versus Non-Round Nuclei,. Blood, 2011, 118, 3538-3538.	1.4	16
51	Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion. Blood Cancer Journal, 2019, 9, 81.	6.2	14
52	Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements. Journal of Physical Education and Sports Management, 2019, 5, a004077.	1.2	14
53	The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma. Clinical Cancer Research, 2021, 27, 5430-5439.	7.0	14
54	The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms. American Journal of Clinical Pathology, 2018, 150, 375-384.	0.7	13

#	Article	IF	Citations
55	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. American Journal of Hematology, 2019, 94, E117-E120.	4.1	13
56	Systematic use of fluorescence inâ€situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms. Histopathology, 2020, 76, 1042-1054.	2.9	13
57	<scp>FGFR</scp>1 and <scp>FGFR</scp>2 in fibrolamellar carcinoma. Histopathology, 2016, 68, 686-692.	2.9	12
58	A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow. American Journal of Clinical Pathology, 2018, 150, 421-431.	0.7	12
59	Assessment of fixedâ€duration therapies for treatmentâ€naÃ¯ve <scp>WaldenstrÃ¶m</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	4.1	12
60	Disease outcomes and biomarkers of progression in smouldering WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	2.5	12
61	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€parametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	4.1	11
62	Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression. Head and Neck Pathology, 2020, 14, 951-965.	2.6	11
63	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. Transplantation and Cellular Therapy, 2021, 27, 165.e1-165.e11.	1.2	11
64	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer Journal, 2021, 11, 43.	6.2	11
65	Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer Journal, 2019, 9, 20.	6.2	10
66	Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 Translocation in an Infant Erythroblastic Sarcoma. American Journal of Clinical Pathology, 2021, 156, 129-138.	0.7	10
67	PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. International Journal of Gynecological Pathology, 2018, 37, 537-546.	1.4	9
68	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. Leukemia and Lymphoma, 2019, 60, 990-999.	1.3	9
69	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	5.5	9
70	Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series. Blood Cancer Journal, 2022, 12, 11.	6.2	9
71	Brain Metastasis of Crystal-Deficient, CD68-Positive Alveolar Soft Part Sarcoma: Ultrastructural Features and Differential Diagnosis. Ultrastructural Pathology, 2015, 39, 69-77.	0.9	8
72	Detection of a cryptic NUP214/ABL1 gene fusion by mate-pair sequencing (MPseq) in a newly diagnosed case of pediatric T-lymphoblastic leukemia. Journal of Physical Education and Sports Management, 2019, 5, a003533.	1.2	8

#	Article	IF	Citations
73	Constitutional chromosome rearrangements that mimic the 2017 world health organization â€œacute myeloid leukemia with recurrent genetic abnormalitiesâ€: A study of three cases and review of the literature. Cancer Genetics, 2019, 230, 37-46.	0.4	8
74	Fluorescence inâ€situ hybridisation for TP63 rearrangements in T cell lymphomas: singleâ€site experience of 470 patients and implications for clinical testing. Histopathology, 2020, 76, 481-485.	2.9	8
75	Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing. Annals of Diagnostic Pathology, 2020, 46, 151533.	1.3	8
76	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer Journal, 2021, 11, 18.	6.2	8
77	Clinical utility of next generation sequencing to detect IGH/IL3 rearrangements [t(5;14)(q31.1;q32.1)] in B-lymphoblastic leukemia/lymphoma. Annals of Diagnostic Pathology, 2021, 53, 151761.	1.3	8
78	Ovarian Hemangiomas Do Not Harbor EWSR1 Rearrangements. International Journal of Gynecological Pathology, 2015, 34, 437-444.	1.4	7
79	Environmental exposures as a risk factor for fibrolamellar carcinoma. Modern Pathology, 2017, 30, 892-896.	5.5	7
80	Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival. Biology of Blood and Marrow Transplantation, 2017, 23, 782-789.	2.0	7
81	Identification of a Novel ZBTB20-JAK2 Fusion by Mate-Pair Sequencing in a Young Adult With B-Lymphoblastic Leukemia/Lymphoma. Mayo Clinic Proceedings, 2019, 94, 1381-1384.	3.0	7
82	Aurora kinase B-phosphorylated HP1Î± functions in chromosomal instability. Cell Cycle, 2019, 18, 1407-1421.	2.6	7
83	Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk From Intermediate- and High-Risk Prostate Cancer. Mayo Clinic Proceedings, 2019, 94, 27-36.	3.0	7
84	Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia. Human Pathology, 2019, 89, 109-114.	2.0	7
85	Characterization of a cryptic PML-RARA fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative RARA FISH studies. Leukemia and Lymphoma, 2020, 61, 975-978.	1.3	7
86	Cryptic and atypical <scp>KMT2Aâ€USP2</scp> and <scp>KMT2Aâ€USP8</scp> rearrangements identified by mate pair sequencing in infant and childhood leukemia. Genes Chromosomes and Cancer, 2020, 59, 422-427.	2.8	7
87	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122.	6.2	7
88	Outcomes following venetoclaxâ€based treatment in therapyâ€related myeloid neoplasms. American Journal of Hematology, 2022, 97, 1013-1022.	4.1	7
89	Typical, atypical and cryptic t(15;17)(q24;q21) (PML::RARA) observed in acute promyelocytic leukemia: A retrospective review of 831 patients with concurrent chromosome and PML::RARA dualâ€color dualâ€fusion FISH studies. Genes Chromosomes and Cancer, 2022, 61, 629-634.	2.8	7
90	Characterizing false-positive fluorescence in situ hybridization results by mate-pair sequencing in a patient with chronic myeloid leukemia and progression to myeloid blast crisis. Cancer Genetics, 2020, 243, 48-51.	0.4	6

#	Article	IF	Citations
91	Comparative study of therapyâ€related and de novo adult bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2022, 196, 963-968.	2.5	6
92	Prognostic significance of acquired 1q22 gain in multiple myeloma. American Journal of Hematology, 2021, , .	4.1	6
93	MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. Blood Cancer Journal, 2021, 11, 184.	6.2	6
94	CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma. Cancers, 2022, 14, 2299.	3.7	6
95	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. Blood Cancer Journal, 2022, 12, .	6.2	6
96	Secondary Philadelphia chromosome and erythrophagocytosis in a relapsed acute myeloid leukemia after hematopoietic cell transplantation. Cancer Genetics, 2014, 207, 268-271.	0.4	5
97	Defining Lymphoplasmacytic Lymphoma. American Journal of Clinical Pathology, 2018, 150, 168-176.	0.7	5
98	HepaticYAP1-TFE3Rearranged Epithelioid Hemangioendothelioma. Case Reports in Gastrointestinal Medicine, 2019, 2019, 1-5.	0.3	5
99	Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy. Cancer Genetics, 2019, 237, 51-54.	0.4	5
100	Identification of a novel <scp>KMT2A</scp>/<scp>GIMAP8</scp> gene fusion in a pediatric patient with acute undifferentiated leukemia. Genes Chromosomes and Cancer, 2021, 60, 108-111.	2.8	5
101	BRAF Rearrangements and BRAF V600E Mutations Are Seen in a Subset of Pancreatic Carcinomas With Acinar Differentiation. Archives of Pathology and Laboratory Medicine, 2022, 146, 840-845.	2.5	5
102	Clinical utility of fluorescence in situ hybridizationâ€based diagnosis of BCRâ€ABL1 like (<scp>P</scp>hiladelphia chromosome like) <scp>B</scp>â€cute lymphoblastic leukemia. American Journal of Hematology, 2020, 95, E68-E72.	4.1	4
103	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISHâ€based algorithm distinguishes prognostic groups and outcomes. Blood Cancer Journal, 2021, 11, 156.	6.2	4
104	Gene fusions in gastrointestinal tract cancers. Genes Chromosomes and Cancer, 2022, 61, 285-297.	2.8	4
105	A nearâ€haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed Bâ€lymphoblastic leukemia. Genes Chromosomes and Cancer, 2019, 58, 665-668.	2.8	3
106	Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion. Cancer Genetics, 2020, 241, 67-71.	0.4	3
107	Spurious <scp>CD34</scp> expression in Bâ€cell lymphoma due to nonspecific binding to <scp>PerCPâ€Cy5</scp>.5 fluorochrome conjugates: A rare phenomenon and a diagnostic pitfall. Cytometry Part B - Clinical Cytometry, 2022, 102, 326-328.	1.5	3
108	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. American Journal of Hematology, 2018, 93, E355-E357.	4.1	2

#	Article	IF	Citations
109	Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: AÂCase of Unrecognized t(2;11) Structural Variation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 598-602.	0.4	2
110	Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target. Leukemia and Lymphoma, 2019, 60, 821-824.	1.3	2
111	Case Report with Review of the Literature: Uveal Melanoma in a Patient with Carney Complex â€“ Another Rare Component of the Syndrome?. Ocular Oncology and Pathology, 2020, 6, 311-317.	1.0	2
112	Adult Philadelphia-like B-cell acute lymphoblastic leukemia: Characteristics, outcomes, and role of allogeneic hematopoietic cell transplantation in comparison to Philadelphia-positive and Philadelphia-negative acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2021, 39, 7022-7022.	1.6	2
113	Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. Genes Chromosomes and Cancer, 2021, 60, 678-686.	2.8	2
114	Plasma Cell Folate Receptor Overexpression Differentiates Multiple Myeloma from Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma.. Blood, 2004, 104, 3649-3649.	1.4	2
115	Mediastinal B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements. Journal of Hematopathology, 2022, 15, 151-155.	0.4	2
116	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E398-E401.	4.1	1
117	Characterization of a cryptic KMT2A/AFF1 gene fusion by mate-pair sequencing (MPseq) in a young adult with newly diagnosed B-lymphoblastic leukemia. Journal of Hematopathology, 2019, 12, 99-104.	0.4	1
118	Siblings with ETV6/RUNX1-positive B-lymphoblastic leukemia: A single site experience and review of the literature. Annals of Diagnostic Pathology, 2020, 48, 151588.	1.3	1
119	Twin-to-twin transmission of transient abnormal myelopoiesis without constitutional trisomy 21: A case report. Cancer Genetics, 2020, 244, 62-64.	0.4	1
120	Rare MDM2 amplification in a fat-predominant angiomyolipoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 661-666.	2.8	1
121	Characteristics of patients with myelodysplastic syndrome with balanced translocations. British Journal of Haematology, 2020, 190, 244-248.	2.5	1
122	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. Annals of Hematology, 2020, 99, 513-518.	1.8	1
123	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.	1.4	1
124	In-111DAC Is a Novel Technique To Image Multiple Myeloma.. Blood, 2006, 108, 3488-3488.	1.4	1
125	OUP accepted manuscript. Laboratory Medicine, 2021, , .	1.2	1
126	Whole Arm Duplication of 1q in Myeloid Neoplasm, with Emphasis On Derivative (1;7)(q10;p10).. Blood, 2009, 114, 4238-4238.	1.4	1

#	Article	IF	Citations
127	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	1.4	1
128	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. Blood, 2019, 134, 1800-1800.	1.4	1
129	Detection of a Cryptic KMT2A/AFDN Gene Fusion [ins(6;11)(q27;q23q23)] in a Pediatric Patient with Newly Diagnosed Acute Myeloid Leukemia. Laboratory Medicine, 2022, 53, e95-e99.	1.2	1
130	Characterization of Atypical t(11;14) CCND1/IGH Translocations in Multiple Myeloma. Blood, 2021, 138, 3771-3771.	1.4	1
131	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. Blood, 2021, 138, 3691-3691.	1.4	1
132	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. Blood, 2020, 136, 26-27.	1.4	1
133	A Novel USP25::PDGFRA Gene Fusion in a 78 Year Old Patient with a Myeloid Neoplasm. Laboratory Medicine, 2022, 53, e134-e138.	1.2	1
134	Identification of EWSR1 rearrangements in patients with immature hematopoietic neoplasms: A case series and review of literature. Annals of Diagnostic Pathology, 2022, 58, 151942.	1.3	1
135	Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. Leukemia and Lymphoma, 2022, , 1-4.	1.3	1
136	A 10-Year Review of KMT2A Gene Fusion Partners Observed in Pediatric T-Lymphoblastic Leukemia/Lymphoma: The Mayo Clinic Experience. American Journal of Clinical Pathology, 2018, 150, S132-S132.	0.7	0
137	Use of Mate-Pair Sequencing (MPseq) to Elucidate a Complex BCR-ABL1 Rearrangement Observed in a Newly Diagnosed Case of Chronic Myeloid Leukemia. American Journal of Clinical Pathology, 2018, 150, S131-S132.	0.7	0
138	14. Clinical mate-pair sequencing reveals complex genomic rearrangements in B-lymphoblastic leukemia/lymphoma (B-ALL). Cancer Genetics, 2018, 224-225, 55-56.	0.4	0
139	12. Mate pair sequencing: Unveiling underappreciated complexity and providing clarity to the previously unanswered questions of cytogenetics. Cancer Genetics, 2018, 224-225, 54-55.	0.4	0
140	13. Clinical utility of mate pair sequencing to detect diagnostic and prognostic chromosomal rearrangements and copy number changes in patients with acute myeloid leukemia. Cancer Genetics, 2018, 224-225, 55.	0.4	0
141	Characterization of a t(1;2)(p36;p21) involving the PRDM16 gene region by mate-pair sequencing (MPseq) in a patient with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes. Journal of Hematopathology, 2019, 12, 85-90.	0.4	0
142	Mate pair sequencing outperforms fluorescence in situ hybridization and improves diagnostic yield in the genomic characterization of multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e58.	0.4	0
143	Detection of a Cryptic EP300/ZNF384 Gene Fusion by Chromosomal Microarray and Next-Generation Sequencing Studies in a Pediatric Patient with B-Lymphoblastic Leukemia. Laboratory Medicine, 2021, 52, 297-302.	1.2	0
144	Erythroblastic sarcoma transformation from a chronic myeloid neoplasm with FGFR1 rearrangement presenting as a pleural effusion: a case report. Journal of Hematopathology, 2021, 14, 157-162.	0.4	0

#	Article	IF	Citations
145	Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e710-e713.	0.4	0
146	Myeloma with t(11;14) and CD20+ Plasma Cells: Response to Rituximab.. Blood, 2005, 106, 5178-5178.	1.4	0
147	Isolated Trisomy 8 in the Myelodysplastic Syndromes.. Blood, 2009, 114, 2785-2785.	1.4	0
148	FISH Redoux â€" A Novel Way to Emulate CLL Leukemic Cells From Buffy Coat Samples. Blood, 2010, 116, 3606-3606.	1.4	0
149	Very High Risk CLL Characterized by a â€œDouble Hitâ€•Clone with Both 11q22 and 17p13 Deletion.. Blood, 2012, 120, 2486-2486.	1.4	0
150	Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience. Blood, 2016, 128, 5541-5541.	1.4	0
151	Utilization of Mate-Pair Sequencing to Characterize Complex and Novel TCF3 Translocations. Blood, 2016, 128, 4086-4086.	1.4	0
152	Outcome of patients younger than 50 years old diagnosed with myelodysplastic syndromes (MDS): Single institution experience.. Journal of Clinical Oncology, 2017, 35, e18560-e18560.	1.6	0
153	The impact of clonal size on the revised international prognostic scoring system (R-IPSS) in myelodysplastic syndromes (MDS) with a single cytogenetic abnormality.. Journal of Clinical Oncology, 2018, 36, 7068-7068.	1.6	0
154	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome per 2017 WHO guideline compared to de novo MDS.. Journal of Clinical Oncology, 2018, 36, e19026-e19026.	1.6	0
155	Abstract 655: Hyperdiploidy in plasma cell disorders using multi-parametric flow cytometry (MFC) vs. FISH. , 2018, , .		0
156	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. Blood, 2018, 132, 5510-5510.	1.4	0
157	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	1.4	0
158	Reassignment of HER2 status for subgroups of breast cancer according to the 2018 updated American Society of Clinical Oncology and College of American Pathologists guidelines: The impact of combined immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) reflex testing in a large national reference laboratory.. Journal of Clinical Oncology, 2019, 37, 3144-3144.	1.6	0
159	Identification of Targetable Tumor Associated Proteins in Adult T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Including a Novel CC-Chemokine 4 (CCR4)-Positive T-ALL/LBL with Unique Immunophenotype. Blood, 2019, 134, 5210-5210.	1.4	0
160	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. Blood, 2019, 134, 2588-2588.	1.4	0
161	Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions. Cancer Genetics, 2021, 260-261, 1-5.	0.4	0
162	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). Blood, 2021, 138, 2285-2285.	1.4	0

#	Article	IF	Citations
163	False-Negative Centromere 15 Probe Results in Association with African Ancestry in Plasma Cell Dyscrasias. Blood, 2021, 138, 4101-4101.	1.4	0
164	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. Blood, 2020, 136, 9-10.	1.4	0
165	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. Blood, 2020, 136, 44-44.	1.4	0
166	Heterogeneity of MYC Abnormalities in Multiple Myeloma. Blood, 2020, 136, 2-3.	1.4	0
167	Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. Blood, 2020, 136, 21-22.	1.4	0
168	BAP1 Immunostain Status in Intraocular Biopsy Specimens for Uveal Melanoma Highly Correlates with Other Prognostic Markers. Ocular Oncology and Pathology, 2022, 8, 22-29.	1.0	0